The global gynecological cancers therapeutics market is expected to grow at a significant CAGR during the forecast period (2021-2027). Gynecological drugs are becoming more common among women, and they are also becoming one of the main causes of death in many areas. There are a variety of drugs on the market to treat various forms of gynaecological cancers. With the growing number of medications currently in clinical development and approval, advanced cancer therapies and novel drugs are being presented.

In the global gynaecological cancer therapeutics market, the antitumor antibiotic medication class is expected to acquire the most share. Antitumor antibiotics are widely used as they assist to inhibit or reduce the growth of cancer cells. Furthermore, these drugs are effective in the treatment of cancer. Hospital pharmacies are expected to be the main distribution channel for gynaecological cancer medications among the distribution channels. Due to many drugs being only allowed for sale by hospital pharmacies in government hospitals, hospital pharmacies are the major distributors of gynaecological cancer drugs. 

Furthermore, the increased availability of generic cancer medications is pushing sales of gynaecological cancer drugs through hospital pharmacies. In terms of revenue, uterine cancer is expected to account for the major share during the forecast period. The most prevalent type of gynaecological cancer identified in women is uterine cancer. As a result, the development of new therapies and medications to treat uterine cancer is moving at a faster pace. Furthermore, endometrial cancer, or cancer of the uterus' inner lining, is the second most prevalent cancer in women, particularly in developed countries.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: GlaxoSmithKline (GSK), Johnson & Johnson (Alza Corporation), Dr Reddy’s Laboratories, Merck & Co., Bristol-Myers Squibb, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Gynecological Cancers Therapeutics Market by Segment

By Drug Class

• Alkylating Agent

• Plant Alkaloid

• Anthracyclines

• Antitumor Antibiotic

• Other Drug Class 

By Distribution Channel 

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy 

By Indication 

• Cervical Cancer

• Uterine Cancer

• Ovarian & Fallopian Tube Cancer

• Vulvar Cancer

• Vaginal Cancer

Global Gynecological Cancers Therapeutics Market by Region